Depatuxizumab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A humanized monoclonal antibody (MoAb) against human epidermal growth factor receptor (EGFR) with antineoplastic activity. Depatuxizumab targets the EGFR deletion variant, de2-7 EGFR as well as wild-type EGFR expressed in cells overexpressing the receptor, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization result in an inhibition in signal transduction and anti-proliferative effects. This MoAb targets cells expressing aberrant EGFR, hence making it an ideal candidate for generation of radioisotope or toxin conjugates.

**Synonyms:** - ABT-806 - DEPATUXIZUMAB - Immunoglobulin G1, Anti-(Human Epidermal Growth Factor Receptor) (Human-mus musculus Monoclonal ABT-806 Heavy Chain), Disulfide with Human-mus musculus Monoclonal ABT-806 Light Chain, Dimer - anti-EGFR MoAb ABT-806 - anti-EGFR mAb ABT-806 - mAb-806